1nd3: Difference between revisions
New page: left|200px<br /><applet load="1nd3" size="450" color="white" frame="true" align="right" spinBox="true" caption="1nd3, resolution 2.8Å" /> '''The structure of HRV1... |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:1nd3.jpg|left|200px]]<br /><applet load="1nd3" size=" | [[Image:1nd3.jpg|left|200px]]<br /><applet load="1nd3" size="350" color="white" frame="true" align="right" spinBox="true" | ||
caption="1nd3, resolution 2.8Å" /> | caption="1nd3, resolution 2.8Å" /> | ||
'''The structure of HRV16, when complexed with pleconaril, an antiviral compound'''<br /> | '''The structure of HRV16, when complexed with pleconaril, an antiviral compound'''<br /> | ||
==Overview== | ==Overview== | ||
Pleconaril is a broad-spectrum antirhinovirus and antienterovirus compound | Pleconaril is a broad-spectrum antirhinovirus and antienterovirus compound that binds into a hydrophobic pocket within viral protein 1, stabilizing the capsid and resulting in the inhibition of cell attachment and RNA uncoating. When crystals of human rhinovirus 16 (HRV16) and HRV14 are incubated with pleconaril, drug occupancy in the binding pocket is lower than when pleconaril is introduced during assembly prior to crystallization. This effect is far more marked in HRV16 than in HRV14 and is more marked with pleconaril than with other compounds. These observations are consistent with virus yield inhibition studies and radiolabeled drug binding studies showing that the antiviral effect of pleconaril against HRV16 is greater on the infectivity of progeny virions than the parent input viruses. These data suggest that drug integration into the binding pocket during assembly, or at some other late stage in virus replication, may contribute to the antiviral activity of capsid binding compounds. | ||
==About this Structure== | ==About this Structure== | ||
1ND3 is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Human_rhinovirus_2 Human rhinovirus 2] with ZN and W11 as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http:// | 1ND3 is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Human_rhinovirus_2 Human rhinovirus 2] with <scene name='pdbligand=ZN:'>ZN</scene> and <scene name='pdbligand=W11:'>W11</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1ND3 OCA]. | ||
==Reference== | ==Reference== | ||
| Line 13: | Line 13: | ||
[[Category: Human rhinovirus 2]] | [[Category: Human rhinovirus 2]] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
[[Category: Bator, C | [[Category: Bator, C M.]] | ||
[[Category: Chakravarty, S.]] | [[Category: Chakravarty, S.]] | ||
[[Category: Diana, G.]] | [[Category: Diana, G.]] | ||
[[Category: Pevear, D | [[Category: Pevear, D C.]] | ||
[[Category: Rossmann, M | [[Category: Rossmann, M G.]] | ||
[[Category: Simpson, A | [[Category: Simpson, A A.]] | ||
[[Category: Skochko, G | [[Category: Skochko, G A.]] | ||
[[Category: Tull, T | [[Category: Tull, T M.]] | ||
[[Category: Zhang, Y.]] | [[Category: Zhang, Y.]] | ||
[[Category: W11]] | [[Category: W11]] | ||
| Line 30: | Line 30: | ||
[[Category: rhinovirus]] | [[Category: rhinovirus]] | ||
''Page seeded by [http:// | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:04:46 2008'' | ||
Revision as of 15:04, 21 February 2008
|
The structure of HRV16, when complexed with pleconaril, an antiviral compound
OverviewOverview
Pleconaril is a broad-spectrum antirhinovirus and antienterovirus compound that binds into a hydrophobic pocket within viral protein 1, stabilizing the capsid and resulting in the inhibition of cell attachment and RNA uncoating. When crystals of human rhinovirus 16 (HRV16) and HRV14 are incubated with pleconaril, drug occupancy in the binding pocket is lower than when pleconaril is introduced during assembly prior to crystallization. This effect is far more marked in HRV16 than in HRV14 and is more marked with pleconaril than with other compounds. These observations are consistent with virus yield inhibition studies and radiolabeled drug binding studies showing that the antiviral effect of pleconaril against HRV16 is greater on the infectivity of progeny virions than the parent input viruses. These data suggest that drug integration into the binding pocket during assembly, or at some other late stage in virus replication, may contribute to the antiviral activity of capsid binding compounds.
About this StructureAbout this Structure
1ND3 is a Protein complex structure of sequences from Human rhinovirus 2 with and as ligands. Full crystallographic information is available from OCA.
ReferenceReference
Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds., Zhang Y, Simpson AA, Ledford RM, Bator CM, Chakravarty S, Skochko GA, Demenczuk TM, Watanyar A, Pevear DC, Rossmann MG, J Virol. 2004 Oct;78(20):11061-9. PMID:15452226
Page seeded by OCA on Thu Feb 21 14:04:46 2008